Although two meta-analyses had been published in 2014 [42] and 2015 [43], some results in their work still need to be advanced: Firstly, this two analyses only examined the correlation between IL-17 expression and clinical outcome in NSCLC patients. This evidence concerns the gene IL17A and non-small cell lung carcinoma.